19 completed, 3 recruiting, 1 enrolling by invitation, 1 not yet recruiting. 12 Phase 3, 8 Phase 2, 6 Phase 4, 1 Early Phase 1, 1 Not applicable.
Follow netarsudil: new trials by email Literature Review of netarsudil trials Research Report on netarsudil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution - Open Angle Glaucoma (OAG), Glaucoma | Phase 4 | Recruiting | Brett King | 13 | 2026-10-01 | 2026-10-28 |
| Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Rocklatan (Netarsudil 0.02%/ latanoprost 0.005), Latanoprost (0.005%) - Ocular Hypertension, Suspect Glaucoma | Phase 4 | Recruiting | University of Maryland, Baltimore | 50 | 2026-07-02 | 2026-07-02 |
| 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Recruiting | Mayo Clinic | 30 | 2025-11-21 | 2026-05-01 |
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 3 | Completed | Alcon Research | 489 | 2025-09-02 | 2026-04-21 |
| Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane - Primary Open Angle Glaucoma | Phase 4 | Not yet recruiting | Center for Sight Las Vegas | 68 | 2025-07-15 | 2025-07-03 |
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy Netarsudil 0.02% Ophthalmic Solution, artificial tear substitute - Fuchs Endothelial Corneal Dystrophy, Cataract | Enrolling by invitation | University Hospital Dubrava | 50 | 2025-04-01 | 2026-09-09 | |
| Next Generation Rocklatan AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 426 | 2024-09-04 | 2025-11-18 |
| Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost Netarsudil, Brimonidine - Normal Tension Glaucoma | Phase 4 | Completed | Westlake Eye Specialists | 100 | 2024-06-13 | 2025-10-22 |
| A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 / Phase 3 | Unknown | Wills Eye | 80 | 2023-02-06 | 2024-07-30 |
| Rocklatan® Evaluation Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution - Glaucoma | Phase 4 | Completed | Aerie Pharmaceuticals | 136 | 2022-03-28 | 2024-04-03 |
| Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity Netarsudil 0.02% QD, Timolol maleate 0.5% BID - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Not applicable | Withdrawn | University of California, San Diego | 2021-12-01 | 2022-03-31 | |
| Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration Netarsudil, Placebo - Fuchs' Endothelial Dystrophy | Phase 2 / Phase 3 | Terminated | Price Vision Group | 19 | 2019-07-22 | 2023-02-06 |
| Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty Netarsudil 0.02% Ophthalmic Solution - Fuchs' Endothelial Dystrophy, Cataract | Early Phase 1 | Completed | Massachusetts Eye and Ear Infirmary | 10 | 2018-10-02 | 2021-01-26 |
| Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation Netarsudil, Placebo - Fuchs' Endothelial Dystrophy, Bullous Keratopathy | Phase 3 | Completed | Cornea Research Foundation of America | 120 | 2017-09-05 | 2021-02-12 |
| Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension Netarsudil/Latanoprost 0.02%/0.005%, GANFORT® - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 436 | 2017-09-05 | 2022-01-31 |
| Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle - Ocular Hypertension, Open Angle Glaucoma | Phase 2 | Completed | Aerie Pharmaceuticals | 12 | 2016-07-01 | 2018-04-17 |
| Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005% - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 750 | 2016-02-01 | 2019-05-21 |
| Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005% - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 718 | 2015-09-18 | 2019-06-04 |
| Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 708 | 2015-09-01 | 2018-04-06 |
Showing 20 of 27. Sign in to see all of them.
Glaucoma, Open-Angle (16) · Ocular Hypertension (16) · Glaucoma (10) · Fuchs' Endothelial Dystrophy (4) · Cataract (2) · Corneal Edema (2) · Hereditary Sensory and Autonomic Neuropathies (1) · Low Tension Glaucoma (1) · Retinal Detachment (1) · Vitreoretinopathy, Proliferative (1)
Aerie Pharmaceuticals (13) · Alcon Research (2) · University Hospital Dubrava (2) · Brett King (1) · Center for Sight Las Vegas (1) · Cornea Research Foundation of America (1) · Massachusetts Eye and Ear Infirmary (1) · Mayo Clinic (1) · Price Vision Group (1) · University of California, San Diego (1) · University of Maryland, Baltimore (1) · Westlake Eye Specialists (1) · Wills Eye (1)
United States (23) · Croatia (2) · Austria (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Latvia (1) · Poland (1) · Spain (1) · United Kingdom (1)
Theresa Heah, MD (7) · Francis W Price, Jr, MD (2) · Theresa Heah, MD, MBA (2) · Andrew Camp, MD (1) · Arthur J Sit, MD, MS (1) · Emma E Davies (1) · Jason Hsu, MD (1) · Josip Pavan, MD, PhD (1) · Josip Pavan, prof.dr.sc. (1) · Michelle Senchyna (1) · Nancy Ramirez (1) · Nancy Ramirez, M.S. (1) · Osamah Saeedi, MD (1)
PMID 32166538, PMID 26209587, PMID 31981106, PMID 33045216, PMID 33244711, PMID 33250082, PMID 42568743